埃达拉德克斯本醇通过向脑缺血/再输液损伤中的NRF2/ARE和NF-κB/AIM2通路来保护神经功能
Hui Zhang1,2, Can Zhu2,2, Xingyu Zhou2,2
1Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Neurodegenerative Diseases, Changsha Medical University, Changsha, China.
Frontiers in pharmacology
|May 12, 2025
概括
埃达拉德克斯本醇 (Eda-Dex) 降低了大鼠中风后的大脑损伤和炎症. 这种神经保护作用是通过调节NRF2/ARE和NF-κB/AIM2通路来实现的,这为中风治疗提供了潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 埃达拉德克斯本醇 (Eda-Dex) 是一种神经保护剂,用于中风治疗.
- 埃达-德克斯的确切作用机制尚不清楚.
研究的目的:
- 在大脑缺血/反损伤 (CIRI) 的大鼠模型中研究 Eda-Dex 的神经保护机制.
- 阐明 Eda-Dex 在调节氧化应激和炎症通路中的作用.
主要方法:
- 使用中脑动脉阻塞建立了CIRI的老鼠模型.
- 评估了神经学缺陷,心脏病发作大小和脑血流 (CBF).
- 评估行为变化,氧化应激标志物和炎症路径组件 (NRF2/ARE,NF-κB/AIM2).
主要成果:
- 在CIRI大鼠中,Eda-Dex显著改善了神经学分数,减少了心脏病发作的大小,并增加了CBF.
- 埃达-德克斯减轻了氧化应激和炎症,上调NRF2/ARE通路组件和下调NF-κB/AIM2通路组件.
- 组织学分析显示,大脑损伤减少,神经元恢复,质细胞活化减少.
结论:
- 埃达-德克斯在CIRI大鼠中显示出显著的神经保护作用.
- 这些效应归因于通过NRF2/ARE和NF-κB/AIM2通路对氧化应激和炎症的协同抑制.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
190
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
190
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Transducer Mechanism: Nuclear Receptors
1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
402
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
402
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K


